Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARE-HPV in Persistent High-Risk HPV Genital Infection
NCT07601074Phase 2Recruiting
- Sponsor
- Daré Bioscience, Inc.
- Start
- Jul 2026
- Primary completion
- Oct 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lopinavir, ritonavir in human papillomavirus infection, sponsored by Daré Bioscience, Inc.. Started Jul 2026; status: recruiting.
02
Drugs
lopinavirritonavir
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT07601074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601074.